Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Diagnostics (Basel) ; 14(10)2024 May 11.
Article in English | MEDLINE | ID: mdl-38786295

ABSTRACT

The purpose of this review is to focus on the diagnostic endoscopic ultrasound of the gastrointestinal tract. In the last decades, EUS has gained a central role in the staging of epithelial and sub-epithelial lesions of the gastrointestinal tract. With the evolution of imaging, the position of EUS in the diagnostic work-up and the staging flow-chart has continuously changed with two extreme positions: some gastroenterologists think that EUS is absolutely indispensable, and some think it is utterly useless. The truth is, as always, somewhere in between the two extremes. Analyzing the most up-to-date and strong evidence, we will try to give EUS the correct position in our daily practice.

2.
Diagnostics (Basel) ; 13(11)2023 May 25.
Article in English | MEDLINE | ID: mdl-37296694

ABSTRACT

INTRODUCTION: Preoperative gastric cancer (GC) staging is the most reliable prognostic factor that affects therapeutic strategies. Contrast-enhanced computed tomography (CECT) and radial endoscopic ultrasound (R-EUS) scans are the most commonly used staging tools for GC. The accuracy of linear EUS (L-EUS) in this setting is still controversial. The aim of this retrospective multicenter study was to evaluate the accuracy of L-EUS and CECT in preoperative GC staging, with regards to depth of tumor invasion (T staging) and nodal involvement (N staging). MATERIALS AND METHODS: 191 consecutive patients who underwent surgical resection for GC were retrospectively enrolled. Preoperative staging had been performed using both L-EUS and CECT, and the results were compared to postoperative staging by histopathologic analysis of surgical specimens. RESULTS: L-EUS diagnostic accuracy for depth of invasion of the GC was 100%, 60%, 74%, and 80% for T1, T2, T3, and T4, respectively. CECT accuracy for T staging was 78%, 55%, 45%, and 10% for T1, T2, T3, and T4, respectively. L-EUS diagnostic accuracy for N staging of GC was 85%, significantly higher than CECT accuracy (61%). CONCLUSIONS: Our data suggest that L-EUS has a higher accuracy than CECT in preoperative T and N staging of GC.

3.
Dig Liver Dis ; 54(11): 1508-1512, 2022 11.
Article in English | MEDLINE | ID: mdl-35614002

ABSTRACT

BACKGROUND AND AIM: Very low-volume bowel preparation (BP) for colonoscopy with 1-liter polyethylene glycol plus ascorbate (1L-PEG-Asc) has displayed high tolerability and quality of bowel cleansing. Concerns have been raised regarding its safety. We aimed to evaluate the incidence of adverse events (AEs) following BP with 1L-PEG-Asc or 2L-PEG-Asc. PATIENTS AND METHODS: From January 2019 to September 2020, data from all consecutive adult outpatients who underwent colonoscopy in Our Unit were collected. AEs were assessed by reviewing the clinical and laboratory data of patients who attended the Emergency Department (ED) of Modena District Hospitals in the 7 days following the colonoscopy, and were classified as "BP-related" or "BP-unrelated". RESULTS: During the study, 4069 (68.03%) and 1912 (31.97%) patients underwent colonoscopy after taking 2L-PEG-Asc or 1L-PEG-Asc, respectively. Regarding AEs, 77 (1.29%) patients attended ED, 53 (53/4069, 1.30%) and 24 (24/1912, 1.25%) after taking 2L-PEG-Asc and 1L-PEG-Asc. BP-related AEs were observed in 5 (5/4069, 0.12%) and 4 (4/1912, 0.21%) patients, respectively. The most frequent BP-related AEs were tachyarrhythmias (6/5981, 0.10%). CONCLUSION: The incidence rate of clinically relevant BP-related AEs is extremely low. This strongly suggests that 1L-PEG-Asc colonoscopy BP is as safe as 2L-PEG-Asc BP in a real-life clinical setting of unselected patients.


Subject(s)
Cathartics , Polyethylene Glycols , Adult , Humans , Cathartics/adverse effects , Polyethylene Glycols/adverse effects , Colonoscopy , Laxatives , Ascorbic Acid/adverse effects
4.
Dig Dis Sci ; 66(7): 2173-2176, 2021 07.
Article in English | MEDLINE | ID: mdl-33835376

ABSTRACT

INTRODUCTION: Small bowel involvement is very common in Crohn's disease. Ileocolonoscopy, cross-sectional imaging modalities, and video capsule endoscopy are the tools currently used to investigate such involvement. AREAS COVERED: Herein we report the case of a 47-year-old man with a history of ileocolic Crohn's disease and persistent, unexplained iron deficiency anemia. EXPERT COMMENTARY: Capsule endoscopy, by accurately identifying small intestinal mucosal lesions, can improve outcomes.


Subject(s)
Capsule Endoscopy/methods , Crohn Disease/pathology , Intestine, Small/pathology , Humans , Male , Middle Aged
5.
Dig Dis Sci ; 66(3): 714-722, 2021 03.
Article in English | MEDLINE | ID: mdl-33433808

ABSTRACT

INTRODUCTION: Granular cellular tumors are unusual lesions that can occur in the gastrointestinal tract, where they localize most commonly to the esophagus followed by the colon. AREAS COVERED: We report a case of a young man with a sub-epithelial lesion of the ascending colon, removed by endoscopic submucosal dissection. Histological examination revealed a granular cellular tumor without features of malignancy. We present a systematic review of the English literature evaluating granular cellular tumors of lower gastrointestinal tract. EXPERT COMMENTARY: These tumors are usually asymptomatic and discovered incidentally during endoscopy performed for other reasons. Though their histological behavior is usually benign, 1-2% are malignant. Therefore, it is important that these lesions are excised and adequately pathologically characterized.


Subject(s)
Colonic Neoplasms/pathology , Granular Cell Tumor/pathology , Colectomy/methods , Colon/pathology , Colon/surgery , Colonic Neoplasms/surgery , Endoscopic Mucosal Resection/methods , Granular Cell Tumor/surgery , Humans , Intestinal Mucosa/pathology , Intestinal Mucosa/surgery , Male , Young Adult
8.
J Gastrointestin Liver Dis ; 30(1): 142-146, 2020 Nov 12.
Article in English | MEDLINE | ID: mdl-33118539

ABSTRACT

Sorafenib is currently the gold standard therapy for palliative treatment of advanced hepatocellular carcinoma (HCC) in patients with compensated liver disease. There are few cases reported in literature describing patients with HCC achieving a complete remission (CR) due to Sorafenib therapy. We report the case of a 62-year old patient who obtained CR despite single, long drug discontinuation and kept it without any maintenance therapy. Furthermore, this is the first case describing the onset of a likely IgG4-related retroperitoneal fibrosis and cholangitis during Sorafenib administration. Further studies are required to define the predictors of a good response to Sorafenib and to codify a therapeutic maintenance regimen for patients who achieve CR.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Immunoglobulin G , Liver Neoplasms/drug therapy , Sorafenib/therapeutic use , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/pathology , Humans , Liver Neoplasms/complications , Liver Neoplasms/pathology , Male , Middle Aged , Paraproteinemias/complications , Remission Induction
9.
Dig Liver Dis ; 51(6): 769-773, 2019 06.
Article in English | MEDLINE | ID: mdl-31122823

ABSTRACT

Eosinophilic colitis is a rare entity characterized by the presence of a high eosinophilic infiltrate into the colonic wall in symptomatic patients, more often presenting with abdominal pain or diarrhea. These characteristics distinguish eosinophilic colitis from primary colonic eosinophilia, in which patients are asymptomatic. Primary colonic eosinophilia does not need any therapy, while eosinophilic colitis requires a strict treatment, similar to that of the more codified chronic intestinal inflammatory diseases. To date the lack of codified guidelines regarding the diagnostic criteria and the eosinophil threshold values for each colonic segment are the main diagnostic challenge for eosinophilic colitis. In addition, eosinophilic colitis is a diagnosis of exclusion, once all other causes of colonic eosinophilia (food allergens, infections, drugs, etc.) have been excluded. Several treatment options are available for eosinophilic colitis, although the evidence for most of them is limited to case reports and small case series. We examine the epidemiology, etiology, pathophysiology, diagnostic criteria and therapeutic options of eosinophilic colitis reporting recent evidence from the current literature.


Subject(s)
Colitis/therapy , Colonic Diseases/therapy , Eosinophilia/therapy , Colitis/diagnosis , Colitis/epidemiology , Colonic Diseases/diagnosis , Colonic Diseases/epidemiology , Diagnosis, Differential , Diarrhea/diagnosis , Diarrhea/etiology , Eosinophilia/diagnosis , Eosinophilia/epidemiology , Humans , Intestinal Mucosa/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...